Michael Detke, MD, PhD

Chief Medical Officer

Dr. Detke is a board-certified psychiatrist with over 25 years of research experience with extensive clinical and drug development expertise.   At Lilly, he was Senior Medical Director responsible for the Phase III development for Cymbalta and Phase IV for Prozac. He went on to be Executive Director for Neuroscience Medical Research, overseeing all CNS assets in early phase development.  As the CMO at MedAvante, he led a team dedicated to improving signal detection in CNS clinical trials.  He has consulted to multiple pharma and biotech companies as well as the NIH regarding many aspects of CNS clinical trial design and conduct, and has served on scientific advisory boards, data & safety monitoring boards, etc.  Dr. Detke joined CoMentis in 2014 as CMO and has been integrally involved in the IND and clinical planning for the lead α7 agonist.

Dr. Detke has taught and supervised medical students and residents in patient care as a volunteer (adjunct) Clinical Professor of Psychiatry at Indiana University School of Medicine since 2000.

He earned a B.A. and M.S. in Psychology at Yale University, and M.A., M.D., and Ph.D. degrees at the University of Pennsylvania. He trained in medicine and psychiatry at Harvard Medical School, McLean and Massachusetts General Hospitals.  He has published over 70 manuscripts in peer-reviewed journals, reviews for numerous such journals, and is a member of selective scientific organizations such as ACNP, ASCP, ISCTM and SOBP.